North Carolina State University, Raleigh, NC 27695.
Health Phys. 2023 Mar 1;124(3):217-220. doi: 10.1097/HP.0000000000001653.
Extravasation is the situation in which a nuclear medicine injection deposits some fraction of its radioactivity into the soft tissue rather than the bloodstream and may result in a large local radiation dose to tissue. An understanding of localized radiation dose from such unexpected events can be an important aspect of clinical radiation protection. The aim of this study was to estimate and assess absorbed radiation dose to localized soft tissue for hypothetical scenarios of radiopharmaceutical extravasation. Specifically, the goal was to understand whether a radiopharmaceutical extravasation could exceed the US Nuclear Regulatory Commission's medical event reporting limit of 0.5 Sv dose equivalent to tissue or levels at which tissue damage would be anticipated (1.0 Sv dose equivalent). We used the GATE Monte Carlo simulation software to calculate self-dose to spherical volumes containing uniformly distributed amounts of common radiopharmaceutical isotopes. Simulated volumes, radioactivity levels, and effective half-lives represented real-world nuclear medicine procedures. Chosen scenarios consisted of 50 mCi and 100 mCi 177Lu within 20 cm3 and 40 cm3 tissue volumes and a 60 min biological clearance half-time (59.6 min effective half-life), 6 mCi and 12 mCi 99mTc within 1 cm3 and 5 cm3 tissue volumes and a 120 min biological clearance half-time (90 min effective half-life), and 3 mCi and 6 mCi 18F within 1 cm3 and 5 cm3 tissue volumes with a 30 min biological clearance half-time (23.6 min effective half-life). We calculated absorbed doses to be between 5.5 Gy and 23.5 Gy for 177Lu, between 0.9 Gy and 12.4 Gy for 99mTc, and between 1.5 Gy and 16.2 Gy for 18F. Radiopharmaceutical extravasations can result in tissue doses that surpass both medical event reporting limits and levels at which deterministic effects are expected. Radiation safety programs should include identification, mitigation, dosimetry, and documentation of significant extravasation events.
外渗是指放射性核素注射剂的一部分放射性活性沉积在软组织中而不是血流中,可能导致组织受到大剂量的局部辐射。了解这种意外事件的局部辐射剂量是临床辐射防护的一个重要方面。本研究旨在估计和评估放射性核素外渗的假设情况下局部软组织的吸收辐射剂量。具体来说,目标是了解放射性核素外渗是否会超过美国核管理委员会(NRC)对组织的 0.5 毫希沃特(Sv)剂量当量的医疗事件报告限值,或者是否会达到预计会出现组织损伤的水平(1.0 Sv 剂量当量)。我们使用 GATE 蒙特卡罗模拟软件来计算含有常见放射性核素同位素的均匀分布放射性的球形体积的自剂量。模拟的体积、放射性水平和有效半衰期代表了实际的核医学程序。选择的方案包括 50 mCi 和 100 mCi 的 177Lu 在 20 cm3 和 40 cm3 组织体积内,生物清除半衰期为 60 分钟(59.6 分钟有效半衰期),6 mCi 和 12 mCi 的 99mTc 在 1 cm3 和 5 cm3 组织体积内,生物清除半衰期为 120 分钟(90 分钟有效半衰期),3 mCi 和 6 mCi 的 18F 在 1 cm3 和 5 cm3 组织体积内,生物清除半衰期为 30 分钟(23.6 分钟有效半衰期)。我们计算出的 177Lu 的吸收剂量在 5.5 Gy 到 23.5 Gy 之间,99mTc 的吸收剂量在 0.9 Gy 到 12.4 Gy 之间,18F 的吸收剂量在 1.5 Gy 到 16.2 Gy 之间。放射性核素外渗可导致组织剂量超过医疗事件报告限值和预计出现确定性效应的水平。辐射安全计划应包括对外渗事件的识别、减轻、剂量测定和记录。